Paraganglioma: Difference between revisions

Jump to navigation Jump to search
Michael (talk | contribs)
Michael (talk | contribs)
 
(One intermediate revision by the same user not shown)
Line 140: Line 140:
*[[EMA]] -ve.
*[[EMA]] -ve.
**+ve in [[renal cell carcinoma|RCC]].
**+ve in [[renal cell carcinoma|RCC]].
*ATRX normal/loss.
**Loss of staining a poor prognosticator in pheochromocytoma/paraganglioma.<ref name=pmid40652840>{{cite journal |authors=Wang LL, Wei XJ, Zhang QC, Li F, Chen GY |title=Analysis of clinicopathological and immunohistochemical features of pheochromocytoma/paraganglioma |journal=Ann Diagn Pathol |volume=79 |issue= |pages=152525 |date=December 2025 |pmid=40652840 |doi=10.1016/j.anndiagpath.2025.152525 |url=}}</ref>
Testing for heritable tumours:
*SDHB (SDHx alterations).
*FH (loss in HLRCC).
*2SC (positive in HLRCC).
*CAIX (+ve in VHL-related).
*Alpha-inhibin (+ve in VHL-related and SHDx alterations).


==EM==
==EM==